Anesthetic properties of some fluorinated oxolanes and oxetanes

Anesthesia and Analgesia

Volumn 104, Issue 5, 2007, Pages 1090-1097

  Eger II, Edmond I ^a,c,d   Lemal, David ^b   Laster, Michael J ^a   Liao, Mark ^a   Jankowska, Katarzyna ^a   Raghavanpillai, Anilkumar ^b   Popov, Anatoliy V ^b   Gan, Yonghong ^b   Lou, Yan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Dartmouth College   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIFLUOROMETHYLPERFLUOROOXOLANE; 2,2 BIS(TRIFLUOROMETHYL)OXETANE; 2,2 DIFLUORO 3,4,4 TRIS(TRIFLUOROMETHYL)OXETANE; 2,2 DIFLUORO 4 (TRIFLUOROMETHYL)OXETANE; 2,2 DIFLUORO 4,4 BIS(TRIFLUOROMETHYL)OXETANE; 2,2,3 TRIFLUORO 2,2,3 TRIS(TRIFLUOROMETHYL)OXETANE; 2,2,3 TRIFLUORO 2,4,4 TRIS(TRIFLUOROMETHYL)OXETANE; 2,2,3 TRIFLUORO 3,4 BIS(TRIFLUOROMETHYL)OXETANE; 2,2,3 TRIFLUORO 4,4 BIS(TRIFLUOROMETHYL)OXETANE; 2,3 DIFLUORO 2,4,4 TRIS(TRIFLUOROMETHYL)OXETANE; 2,3,3 TRIFLUORO 2,4 BIS(TRIFLUOROMETHYL)OXETANE; 2,5 BIS(DIFLUOROMETHYL)PERFLUOROOXOLANE; 2,5 BIS(FLUOROMETHYL)PERFLUOROOXOLANE; 3 FLUORO 2,2 BIS(TRIFLUOROMETHYL)OXETANE; 3,3 DIFLUORO 2 (TRIFLUOROMETHYL)OXETANE; 3,3 DIFLUORO 2,2 BIS(TRIFLUOROMETHYL)OXETANE; 3,3 DIFLUORO 2,2,4 TRIS(TRIFLUOROMETHYL)OXETANE; 3,3,4 TRIFLUORO 2,2 BIS(TRIFLUOROMETHYL)OXETANE; 3,3H PERFLUOROOXOLANE; 3,4 DIFLUORO 2,2 BIS(TRIFLUOROMETHYL)OXETANE; 3,4 DIFLUORO 2,2,3 TRIS(TRIFLUOROMETHYL)OXETANE; 3,4H PERFLUOROOXOLANE; 3H PERFLUOROOXOLANE; 4 FLUORO 2,2 BIS(TRIFLUOROMETHYL)OXETANE; ETHER DERIVATIVE; INHALATION ANESTHETIC AGENT; ISOFLURANE; OXETANE DERIVATIVE; SEVOFLURANE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CONVULSION; DRUG EFFECT; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; IRRITABILITY; MALE; MINIMUM LUNG ALVEOLUS CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANESTHETICS, INHALATION; ANIMALS; CENTRAL NERVOUS SYSTEM; ETHERS, CYCLIC; FLUORINE COMPOUNDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES;

EID: 34247470154     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000260299.36174.a8     Document Type: Article

References (22)

1. Vitcha JF. A history of Forane®. Anesthesiology 1971;35:4-7.
2. Ter Riet MF, De Souza GJA, Jacobs JS, et al. Which is most pungent: Isoflurane, sevoflurane or desflurane. Br J Anaesth 2000;85:305-7.
3. Eger EI, II, Bowland T, Ionescu P, et al. Recovery and kinetic characteristics of desflurane and sevoflurane in volunteers after 8-hour exposure, including kinetics of degradation products. Anesthesiology 1997;87:517-26.
4. Mayer J, Boldt J, Rohm KD, Scheuermann K, Suttner SW. Desflurane anesthesia after sevoflurane inhaled induction reduces severity of emergence agitation in children undergoing minor ear-nose-throat surgery compared with sevoflurane induction and maintenance. Anesth Analg 2006;102:400-4.
5. Weiskopf RB, Moore M, Eger EI II, et al. Rapid increase in desflurane concentration is associated with greater transient cardiovascular stimulation than with rapid increase in isoflurane concentration in humans. Anesthesiology 1994;80:1035-45.
6. Laster M, Johnson B, Eger EI II, Taheri S. A method for testing for epinephrine-induced arrhythmias in rats. Anesth Analg 1990;70:654-7.
7. Eger EI II, Koblin DD, Collins PA. Dioxychlorane: a challenge to the correlation of anesthetic potency and lipid solubility. Anesth Analg 1981;60:201-3.
8. Eger EI II, Liu J, Koblin DD, et al. Molecular properties of the "ideal" inhaled anesthetic: Studies of fluorinated methanes, ethanes, propanes and butanes. Anesth Analg 1994;79:245-51.
9. Barlow MG, Coles B, Haszeldine RN. Heterocyclic polyfluorocompounds, Part 31: Photochemical oxetan formation from fluoroketones and perfluoroaldehydes and 1,2-difluoroethylene. J Chem Soc Perk Trans 1980;1:2258-67.
10. Tarrant P, Bull RN. The reaction of some 3- and 4-fluorooxetanes with acids. J Fluorine Chem 1988;40:201-5.
11. Cook EW, Landrum BF. Synthesis of partially fluorinated oxetanes (1). J Heterocycl Chem 1965;2:327-32.
12. Harris JF, Coffman DD. Synthesis of polyfluorooxetanes by photoinitiated addition of fluorocarbonyl compounds to fluoroolefins. J Am Chem Soc 1962;84:1553-61.
13. Brey WS, Brey ML. Nuclear magnetic resonance spectra and structure of fluorinated oxetanes. J Fluorine Chem 2000;102:219-33.
14. Strum DP, Johnson BH, Eger EI II. Stability of sevoflurane in soda lime. Anesthesiology 1987;67:779-81.
15. Taheri S, Halsey MJ, Liu J, et al. What solvent best represents the site of action of inhaled anesthetics in humans, rats and dogs. Anesth Analg 1991;72:627-34.
16. Koblin DD, Chortkoff BS, Laster MJ, et al. Polyhalogenated and perfluorinated compounds that disobey the Meyer-Overton hypothesis. Anesth Analg 1994;79:1043-8.
17. Koblin DD, Fang Z, Eger EI II, et al. Minimum alveolar concentrations (MACs) of noble gases, nitrogen, and sulfur hexafluoride in rats: helium and neon as nonimmobilizers (nonanesthetics). Anesth Analg 1998;87:419-24.
18. Laster MJ, Liu J, Eger EI II, Taheri S. Electrical stimulation as a substitute for the tail clamp in the determination of MAC. Anesth Analg 1993;76:1310-2.
19. De Puy CH, Morris GF, Smith JS, Smat RJ. Electronic effects in eliminations v. bimolecular cis eliminations. 2-arylcyclopentyl tosylates. J Am Chem Soc 1965;87:2421-8.
20. Saunders WH Jr, Cockerill AF. Mechanisms of elimination reactions. New York: Wiley, 1973:116-51.
21. Greenberg A, Liebman JF. Strained organic molecules. New York: Academic Press, 1978:66-94.
22. Gier HT, Searles S. Anaesthetic action and toxicity of oxetanes in white rats. J Med Pharm Chem 1959;1:355-63.